Mereo BioPharma Group Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '20 Dec 16, 2020	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Market Capitalization	33	49	433	254	73	128	Upgrade
Market Cap Growth	-86.16%	-88.62%	70.57%	249.41%	-43.41%	-27.46%	Upgrade
Enterprise Value	3	13	374	221	14	37	Upgrade
PE Ratio	-	-	-	-	-	10.09	Upgrade
PS Ratio	88.53	132.62	-	32.34	-	3.52	Upgrade
PB Ratio	1.08	1.62	8.89	6.40	1.70	1.46	Upgrade
P/TBV Ratio	1.10	1.64	8.99	6.54	1.70	2.02	Upgrade
EV/Sales Ratio	7.26	36.02	-	28.17	-	1.02	Upgrade
Debt / Equity Ratio	0.01	0.01	0.11	0.12	0.30	0.19	Upgrade
Net Debt / Equity Ratio	-1.00	-1.00	-1.04	-1.02	-1.03	-0.88	Upgrade
Net Debt / EBITDA Ratio	1.08	1.08	1.40	1.94	1.01	3.72	Upgrade
Net Debt / FCF Ratio	1.32	1.32	1.93	2.44	1.08	13.43	Upgrade
Asset Turnover	0.01	0.01	-	0.14	-	0.39	Upgrade
Quick Ratio	9.99	9.99	5.28	6.45	2.89	7.66	Upgrade
Current Ratio	10.47	10.47	5.40	6.72	3.09	7.92	Upgrade
Return on Equity (ROE)	-82.21%	-82.21%	-77.58%	-57.81%	-53.63%	34.85%	Upgrade
Return on Assets (ROA)	-39.41%	-39.41%	-39.99%	-23.57%	-28.67%	-13.82%	Upgrade
Return on Invested Capital (ROIC)	-	-	-	-	-825.95%	-	Upgrade
Return on Capital Employed (ROCE)	-92.70%	-92.70%	-73.10%	-47.60%	-99.40%	-18.40%	Upgrade
Earnings Yield	-94.61%	-63.15%	-7.98%	-9.11%	-48.22%	9.91%	Upgrade
FCF Yield	-70.01%	-46.74%	-6.06%	-6.54%	-55.78%	-4.50%	Upgrade
Buyback Yield / Dilution	-7.77%	-7.77%	-12.16%	-9.33%	-8.63%	-63.82%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.